Patents by Inventor Amy L. Simcoe

Amy L. Simcoe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE
    Publication number: 20140309412
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: June 12, 2013
    Publication date: October 16, 2014
    Inventors: Balkrishen Bhat, Anne B. El drup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
  • Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
    Patent number: 8481712
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: July 9, 2013
    Assignees: Merck Sharp & Dohme Corp., ISIS Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
  • Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
    Publication number: 20120165515
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: February 2, 2007
    Publication date: June 28, 2012
    Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano
  • HCV RNA-dependent RNA polymerase
    Patent number: 7569374
    Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: August 4, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Donald J. Graham, Amy L. Simcoe, Steven W. Ludmerer, Osvaldo A. Flores, Robert L. LaFemina
  • HCV RNA-dependent RNA polymerase
    Publication number: 20080187903
    Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.
    Type: Application
    Filed: December 17, 2007
    Publication date: August 7, 2008
    Inventors: Donald J. Graham, Amy L. Simcoe, Steven W. Ludmerer, Osvaldo A. Flores, Robert L. LaFemina
  • HCV RNA-dependent RNA polymerase
    Patent number: 7329732
    Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.
    Type: Grant
    Filed: January 6, 2005
    Date of Patent: February 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Donald J. Graham, Amy L. Simcoe, Steven W. Ludmerer, Osvaldo A. Flores, Robert L. LaFemina
  • Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
    Publication number: 20040072788
    Abstract: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.
    Type: Application
    Filed: May 7, 2003
    Publication date: April 15, 2004
    Inventors: Balkrishen Bhat, Anne B. Eldrup, Thazha P. Prakash, Phillip Dan Cook, Robert L. LaFemina, Amy L. Simcoe, Carrie A. Rutkowski, Mario A. Valenciano